Evidence map›Paper›PMID 29884405›Full record

Trial reportOphthalmology2018

Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration.

Manjit S Mehat, Venki Sundaram, Caterina Ripamonti, Anthony G Robson, Alexander J Smith, Shyamanga Borooah, Martha Robinson, Adam N Rosenthal, William Innes, Richard G Weleber and 10 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase IIControlled Clinical Trial
In one paragraph

Trial report in Ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01469832 (A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial), which is not on this map. Cited by 158 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 5 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01469832 phase1 / phase2completednot on this map

A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

TypeinterventionalSponsorAstellas Institute for Regenerative MedicineRan2011 to 2015Enrolled12ConditionsStargardt's Macular DystrophyArmsMA09-hRPE
3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 5 syntheses or guidelines pooled it, 280 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Uncovering mitochondrial defects in photoreceptors opens therapeutic opportunities for Stargardt disease.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 2 countries.

Manjit S MehatNIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London, London, United Kingdom; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom.
Venki SundaramNIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London, London, United Kingdom; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom.
Caterina RipamontiCambridge Research Systems Ltd., Rochester, United Kingdom.
Anthony G RobsonNIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London, London, United Kingdom; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
Alexander J SmithNIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom.
Shyamanga BorooahUniversity of Edinburgh, Edinburgh, United Kingdom.
Martha RobinsonInstitute of Ophthalmology, University College London, London, United Kingdom.
Adam N RosenthalUniversity College Hospital, London, United Kingdom.
William InnesNewcastle Eye Centre, Newcastle upon Tyne, United Kingdom.
Richard G WeleberCasey Eye Institute, University of Oregon Health & Science University, Portland, Oregon.
Richard W J LeeNIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London, London, United Kingdom; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom.
Michael CrosslandNIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London, London, United Kingdom; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom.
Gary S RubinNIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London, London, United Kingdom; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom.
Baljean DhillonUniversity of Edinburgh, Edinburgh, United Kingdom.
David H W SteelNewcastle Eye Centre, Newcastle upon Tyne, United Kingdom; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Eddy AngladeAstellas Institute for Regenerative Medicine, Marlborough, Massachusetts.
Robert P LanzaAstellas Institute for Regenerative Medicine, Marlborough, Massachusetts.
Robin R AliNIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom; Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan.
Michel MichaelidesNIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London, London, United Kingdom; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom.
James W B BainbridgeNIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and University College London, London, United Kingdom; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom. Electronic address: j.bainbridge@ucl.ac.uk.
Moorfields Eye Hospital NHS Foundation Trust · GBUniversity of Edinburgh · GBNewcastle College · GBOregon Health & Science University · USUniversity College Hospital · GBUniversity College London · GBW.K. Kellogg Foundation · US

Funding

Department of Health NIHR-RP-011-003Medical Research Council MC_PC_13071Wellcome TrustWellcome Trust 099173/Z/12/Z
6 · The paper itself

Abstract

purposeTransplantation of human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells offers the potential for benefit in macular degeneration. Previous trials have reported improved visual acuity (VA), but lacked detailed analysis of retinal structure and function in the treated area.

designPhase 1/2 open-label dose-escalation trial to evaluate safety and potential efficacy (clinicaltrials.gov identifier, NCT01469832).

participantsTwelve participants with advanced Stargardt disease (STGD1), the most common cause of macular degeneration in children and young adults.

methodsSubretinal transplantation of up to 200 000 hESC-derived RPE cells with systemic immunosuppressive therapy for 13 weeks.

main outcome measuresThe primary end points were the safety and tolerability of hESC-derived RPE cell administration. We also investigated evidence of the survival of transplanted cells and measured retinal structure and function using microperimetry and spectral-domain OCT.

resultsFocal areas of subretinal hyperpigmentation developed in all participants in a dose-dependent manner in the recipient retina and persisted after withdrawal of systemic immunosuppression. We found no evidence of uncontrolled proliferation or inflammatory responses. Borderline improvements in best-corrected VA in 4 participants either were unsustained or were matched by a similar improvement in the untreated contralateral eye. Microperimetry demonstrated no evidence of benefit at 12 months in the 12 participants. In one instance at the highest dose, localized retinal thinning and reduced sensitivity in the area of hyperpigmentation suggested the potential for harm. Participant-reported quality of life using the 25-item National Eye Institute Visual Function Questionnaire indicated no significant change.

conclusionsSubretinal hyperpigmentation is consistent with the survival of viable transplanted hESC-derived RPE cells, but may reflect released pigment in their absence. The findings demonstrate the value of detailed analysis of spatial correlation of retinal structure and function in determining with appropriate sensitivity the impact of cell transplantation and suggest that intervention in early stage of disease should be approached with caution. Given the slow rate of progressive degeneration at this advanced stage of disease, any protection against further deterioration may be evident only after a more extended period of observation.

Indexed as

AdultElectroretinographyFemaleFluorescein AngiographyHuman Embryonic Stem CellsHumansImmunosuppressive AgentsMacular DegenerationMaleMiddle AgedPhotoreceptor Cells, VertebrateQuality of LifeRetinal Pigment EpitheliumSickness Impact ProfileSlit Lamp MicroscopyStargardt DiseaseImmunosuppressive Agents

Identifiers

PMID29884405
PMCPMC6195794
OpenAlexW2805339388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.